Analysts at Berenberg have raised their estimates for the global obesity market to $150 billion by 2035, up from $125 billion previously. This revision is the result of positive data on co-morbidities and advances in competing studies. Berenberg recommends buying shares of $LLY+1.1% and Zealand Pharma, while he recommends holding on to shares of $NVO+2.1%.
What are your...
Read more
This sector currently has great potential. However, shares in this sector are already quite expensive. I bought $NVO+2.1% and I don't regret it.